The American subsidiary Just Evotec Biologics by the Hamburg biotech company Evotec has received a contract from the us Department of defense for the development and production of antibodies, to be used for the treatment and prevention of COVID-19. The order is estimated at up to $ 18.2 million, informed the M-Dax-listed company. The aim of the programme is the Ministry of defence quickly and efficiently monoclonal antibodies provide.
Ilka Kopplin
editor in the economy.
F. A. Z.
The response to COVID-19 requires the use of faster, more flexible, scalable and robust development and manufacturing technologies. “Our company and our platform has been designed with the necessary speed safe and effective products can be developed that are needed for the fight against COVID-19 and future pandemics,” said James Thomas of Just Evotec Biologics.
in may, a cooperation discussed
The order of the Ministry of defence is not surprising. In may, Evotec announced to support the search for a remedy against Coronavirus and was entered into with the American subsidiary with headquarters in Seattle, in cooperation with the organization Ology bioservices. That was, in turn, been commissioned by the American Ministry of defence with the search for appropriate antibodies.
at the Time, Evotec announced, Just-Evotec Biologics use your own platform to anti-body to pick with certain properties for the production and storage and to develop on this basis of therapeutics. “Antibody genes sender patient, not necessarily in a stable, producible Biotherapeutics translate,” said Craig Johnstone, chief Executive of Just-Evotec Biologics.
On Wednesday, Evotec announced now, in the framework of the agreement, you will design a highly efficient method of production of two monoclonal antibodies against the Coronavirus for clinical manufacturing. This would be tested in early clinical trials and, ultimately, to the treatment and prevention of SARS-CoV-2 infections.
